Mark A. Velleca
Overview
Mark A. Velleca received $3M in total compensation, including $180K in salary, at Black Diamond Therapeutics in 2023. Mark Velleca also received an average of $2M at G1 Therapeutics from 2016 to 2020.
- 2023
- 2020
- 2019
- 2018
- 2017
- 2016
Black Diamond TherapeuticsPresident and Chief Executive Officer
G1 TherapeuticsFormer Chief Executive Officer and President
G1 TherapeuticsChief Executive Officer and President
G1 TherapeuticsChief Executive Officer and President
G1 TherapeuticsChief Executive Officer and President
G1 TherapeuticsChief Executive Officer and President
Source: SEC filings on April 24, 2024, April 28, 2021, April 24, 2020, April 30, 2019, and April 18, 2018.
Related executives
We found 14 more executives who work or worked at Black Diamond Therapeutics and G1 Therapeutics.
David Epstein
Black Diamond Therapeutics
Chief Executive Officer
Fang Ni
Black Diamond Therapeutics
Chief Financial Officer
Sergey Yurasov
Black Diamond Therapeutics
Chief Medical Officer
John Bailey
G1 Therapeutics
Chief Executive Officer
Jennifer Moses
G1 Therapeutics
Chief Financial Officer
Mark Avagliano
G1 Therapeutics
Chief Business Officer
Brent Hatzis-Schoch
Black Diamond Therapeutics
Chief Operating Officer
Thomas Leggett
Black Diamond Therapeutics
Chief Financial Officer
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019